IPO - Evaxion Biotech A/S

Form Type: 424B4

Filing Date: 2025-01-31

Corporate Action: Ipo

Type: New

Accession Number: 000110465925007684

Filing Summary: Evaxion Biotech A/S is conducting a public offering of up to 3,997,361 American Depositary Shares (ADSs) representing 199,868,050 ordinary shares, accompanied by warrants to purchase 1,998,675 ADSs. The offering is priced at $2.71 per ADS and accompanying Warrant, with total anticipated proceeds of $10,153,297 before expenses. The ADSs are listed on the Nasdaq under the symbol 'EVAX'. The offering will terminate on February 14, 2025, unless terminated earlier at the company’s discretion. The warrants have an exercise price of $2.71 and a five-year term. The company has engaged Lake Street Capital Markets, LLC and JonesTrading Institutional Services LLC as exclusive Placement Agents for this offering, with fees structured based on the gross proceeds. Investors are cautioned about the investment risks highlighted in the prospectus. Expected delivery of the securities is around January 31, 2025, subject to customary closing conditions.

Document Link: View Document

Form Type: F-1/A

Filing Date: 2025-01-28

Corporate Action: Ipo

Type: Update

Accession Number: 000110465925006720

Filing Summary: Evaxion Biotech A/S filed an amendment to its Form F-1 registration statement for a proposed initial public offering. The company aims to offer up to 1,799,336 American Depositary Shares (ADSs) representing an aggregate of 89,966,800 ordinary shares, along with up to 1,799,336 pre-funded warrants and 899,668 warrants to purchase additional ADSs. The offering price for each ADS and accompanying warrant is set at approximately $6.03, based on data from January 24, 2025. The offering will also include provisions for certain purchasers to acquire pre-funded warrants to avoid exceeding ownership limits. The offering must conclude by February 14, 2025, unless terminated earlier. This registration is a critical step for the company, allowing it to access capital for ongoing business operations and initiatives, particularly focusing on AI-based drug discovery and immunology products. The company highlights its status as an emerging growth company subject to reduced reporting requirements. Risks involved in the investment are emphasized, including uncertainties in achieving proposed business objectives. The company engaged Lake Street Capital Markets, LLC and JonesTrading Institutional Services LLC as exclusive Placement Agents for this offering.

Document Link: View Document